Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
MAFG-AS1
Specific or universal ncRNAs
Universal ncRNAs
Class
Long noncoding RNA
Biomarker
None
Biomarker application
Upstream regulatory factors
Not available
Downstream target
miR-339-5p/CDK2
Cancer name
ER+ Breast Cancer
Cancer site
qRT-PCR,Western blot,Dual-luciferase assay
Treatment type
Chemotherapy
Drug
Tamoxifen
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
24(<=50)+26(>50)
Age range and number
Not available
PMID
Description
lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance
Tissue resource
paired of breast cancer specimens and matched normal tissue samples
breast cancer cell lines MCF-7
breast cancer cell lines BT474
breast cancer cell lines T47D
breast cancer cell lines MCF-10A
Experiment
50
Institute
First Affiliated Hospital of China Medical University
American Type Culture Collection
Country
China
United States
Continent
Asia
North Amercian
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.